Emma S Scott1,2, Georgina V Long2,3,4, Alexander Guminski2,3,4, Roderick J Clifton-Bligh1,2, Alexander M Menzies2,3,4, Venessa H Tsang1,2. 1. Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia. 2. Sydney Medical School, The University of Sydney, Sydney, Australia. 3. Melanoma Institute Australia, Sydney, Australia. 4. Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.
Abstract
OBJECTIVE: Endocrine immune-related adverse events (endocrinopathies) are increasingly prevalent with the use of immune checkpoint inhibitors for the treatment of metastatic melanoma and other malignancies. There are no evidence-based guidelines for the screening or management of such patients. To describe the spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors. DESIGN: A prospective study conducted at Melanoma Institute Australia between April 2014 and October 2015. METHODS: A total of 177 patients were treated with (a) ipilimumab (n = 15), (b) anti-PD-1 (nivolumab, pembrolizumab) (n = 103) or (c) combination ipilimumab and anti-PD-1 (n = 59) and were screened and managed for the subsequent endocrinopathies. The main outcome measures were the incidence and kinetics of endocrinopathy by immunotherapy drug class. RESULTS: Thirty-one patients (18%) developed an endocrine immune-related adverse event (thyroid dysfunction: 14%, hypophysitis: 6% and autoimmune diabetes: 0.6%). Combination immunotherapy was more likely to result in a single or multiple endocrinopathy compared to anti-PD-1 monotherapy (27% vs 9% and 7% vs 0% respectively, P < 0.01). Endocrinopathies occurred after a median of 8 weeks from treatment commencement (range: 12-225 days), with combination immunotherapy resulting in significantly earlier onset compared to ipilimumab (median: 30 vs 76 days, P = 0.046). The majority of endocrinopathies were identified in asymptomatic patients with hormonal screening. There were no baseline predictors for endocrinopathy. CONCLUSIONS: Combination immunotherapy has a greater risk of development of endocrinopathy compared to anti-PD-1 monotherapy. Regular biochemical profiling of patients, particularly within the first twelve weeks, results in early detection of endocrinopathy to minimise morbidity.
OBJECTIVE: Endocrine immune-related adverse events (endocrinopathies) are increasingly prevalent with the use of immune checkpoint inhibitors for the treatment of metastatic melanoma and other malignancies. There are no evidence-based guidelines for the screening or management of such patients. To describe the spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors. DESIGN: A prospective study conducted at Melanoma Institute Australia between April 2014 and October 2015. METHODS: A total of 177 patients were treated with (a) ipilimumab (n = 15), (b) anti-PD-1 (nivolumab, pembrolizumab) (n = 103) or (c) combination ipilimumab and anti-PD-1 (n = 59) and were screened and managed for the subsequent endocrinopathies. The main outcome measures were the incidence and kinetics of endocrinopathy by immunotherapy drug class. RESULTS: Thirty-one patients (18%) developed an endocrine immune-related adverse event (thyroid dysfunction: 14%, hypophysitis: 6% and autoimmune diabetes: 0.6%). Combination immunotherapy was more likely to result in a single or multiple endocrinopathy compared to anti-PD-1 monotherapy (27% vs 9% and 7% vs 0% respectively, P < 0.01). Endocrinopathies occurred after a median of 8 weeks from treatment commencement (range: 12-225 days), with combination immunotherapy resulting in significantly earlier onset compared to ipilimumab (median: 30 vs 76 days, P = 0.046). The majority of endocrinopathies were identified in asymptomatic patients with hormonal screening. There were no baseline predictors for endocrinopathy. CONCLUSIONS: Combination immunotherapy has a greater risk of development of endocrinopathy compared to anti-PD-1 monotherapy. Regular biochemical profiling of patients, particularly within the first twelve weeks, results in early detection of endocrinopathy to minimise morbidity.
Authors: Lucie Heinzerling; Enrico N de Toni; Georg Schett; Gheorghe Hundorfean; Lisa Zimmer Journal: Dtsch Arztebl Int Date: 2019-02-22 Impact factor: 5.594
Authors: Chanjuan Ma; F Stephen Hodi; Anita Giobbie-Hurder; Xiaocheng Wang; Jing Zhou; Amy Zhang; Ying Zhou; Fei Mao; Trevor E Angell; Chelsea P Andrews; Jiani Hu; Romualdo Barroso-Sousa; Ursula B Kaiser; Sara M Tolaney; Le Min Journal: Cancer Immunol Res Date: 2019-05-14 Impact factor: 11.151
Authors: Daniel Y Wang; Meghan J Mooradian; DaeWon Kim; Neil J Shah; Sarah E Fenton; Robert M Conry; Rutika Mehta; Ann W Silk; Alice Zhou; Margaret L Compton; Rami N Al-Rohil; Sunyoung Lee; Amber L Voorhees; Lisa Ha; Svetlana McKee; Jacqueline T Norrell; Janice Mehnert; Igor Puzanov; Jeffrey A Sosman; Sunandana Chandra; Geoffrey T Gibney; Suthee Rapisuwon; Zeynep Eroglu; Ryan Sullivan; Douglas B Johnson Journal: Oncoimmunology Date: 2018-10-31 Impact factor: 8.110
Authors: Lee-Shing Chang; Romualdo Barroso-Sousa; Sara M Tolaney; F Stephen Hodi; Ursula B Kaiser; Le Min Journal: Endocr Rev Date: 2019-02-01 Impact factor: 19.871
Authors: L Brilli; R Danielli; M Campanile; C Secchi; C Ciuoli; L Calabrò; T Pilli; A Cartocci; F Pacini; A M Di Giacomo; M G Castagna Journal: J Endocrinol Invest Date: 2020-12-26 Impact factor: 4.256